Aldeyra advances new RASP modulators ADX-743, ADX-248, ADX-631; pediatric ADX-629 top-line results expected 2025

Aldeyra Therapeutics, Inc.

ADX-629 advanced to pediatric cohort in Sjögren-Larsson Syndrome Phase 2; top-line results from ~5 patients expected 2025.
Novel RASP modulator ADX-743 entered IND-enabling studies for obesity; IND submission planned 2025.
ADX-248 selected over ADX-246 for Phase 1/2 in atopic dermatitis; Phase 1 to start H2 2024.
ADX-631 initiated preclinical testing in retinal disease; IND submission for dry AMD/geographic atrophy expected H1 2025.
Investor roundtable webcast June 20, 2024 at 8:00 am ET to discuss these pipeline updates.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.